UZH and Epigem start trial for newly developed instrument
January 15, 2018
CoMMiTMenT partners UZH and Epigem launched the combined Memantine/MeChem trial in Afula Hospital, Israel, in December 2017. MeChem is the result of both partners’ collaborative work within CoMMiTMenT. The diagnostic device could help identify which patients are most likely to benefit from the tested medicine and monitor the impact of different treatment doses on patients and prevention strategies. It could also have applications to other diseases, such as diabetes.
Both PIs, Anna Bogdanova (UZH) and Tim Ryan (Epigem), were present at the launch in Israel. This precedes the involvement of other CoMMiTMenT clinical partners in the near future in the evaluation of the prototype.
More information on the clinical trial can be found here.